meRfi®-GM
Inflammatory Bowel Disease (IBD) & Sphingomyelin
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Several studies have shown that inflammation can affect the sphingolipid salvage pathways. However, less is known about how inflammatory signals influence the regulation of de novo sphingolipid synthesis. Neutral sphingomyelinase 2 plays a role in controlling the inflammatory responses in monocytes and macrophages that are triggered by Tumor Necrosis Factor alfa (TNF-alfa). The inhibition of Acid sphingomyelinase reduces the release of inflammatory cytokines from ma…
References (Sources)
- Acid sphingomyelinase inhibition suppresses lipopolysaccharide- mediated release of inflammatory cytokines from macrophages and protects against disease pathology in dextran sulphate sodium-induced colitis in mice
- Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis
- Neutral sphingomyelinase 2 regulates inflammatory responses in monocytes/macrophages induced by TNF-α.
- PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate
- Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis